摘要
This study examined the effect of small interfering RNA-mediated β-catenin knockdown on the survival,invasion and chemosensitivity of human osteosarcoma cells（U2-OS cells）.The siRNA against β-catenin was constructed and transfected into U2-OS cells.The expression of β-catenin was detected by qRT-PCR and Western blotting.Cell growth and apoptosis was detected in the presence or absence of doxorubicin by MTT and flow cytometry,respectively.Cell invasion ability was measured by transwell assay.The results showed that the transfection of β-catenin siRNA resulted in decreased expression of β-catenin,suppression of invasion and motility of U2-OS cells,reduced chemosensitivity to doxorubicin in vitro,and little change in cell growth and apoptosis.Additionally,down-regulated MT1-MMP expression was found after transfection.It was concluded that knockdown of β-catenin gene may decrease the invasive ability of human osteosarcoma cells through down-regulated MT1-MMP expression,and the chemosensitivity of osteosarcoma cells against doxorubicin.
This study examined the effect of small interfering RNA-mediated β-catenin knockdown on the survival,invasion and chemosensitivity of human osteosarcoma cells（U2-OS cells）.The siRNA against β-catenin was constructed and transfected into U2-OS cells.The expression of β-catenin was detected by qRT-PCR and Western blotting.Cell growth and apoptosis was detected in the presence or absence of doxorubicin by MTT and flow cytometry,respectively.Cell invasion ability was measured by transwell assay.The results showed that the transfection of β-catenin siRNA resulted in decreased expression of β-catenin,suppression of invasion and motility of U2-OS cells,reduced chemosensitivity to doxorubicin in vitro,and little change in cell growth and apoptosis.Additionally,down-regulated MT1-MMP expression was found after transfection.It was concluded that knockdown of β-catenin gene may decrease the invasive ability of human osteosarcoma cells through down-regulated MT1-MMP expression,and the chemosensitivity of osteosarcoma cells against doxorubicin.
基金
supported by a grant from the Major State Basic Research Development Program of China (973 Program) (No. 2002CB513100)
